Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company leading the way in the development of innovative cell therapies for autoimmune diseases and hematologic malignancies. The company's flagship product, NXC-201, is a next-generation CAR-T cell therapy designed to treat relapsed/refractory AL Amyloidosis and multiple myeloma. NXC-201 stands out due to its potential to be the world’s first 'Single-Day CRS' CAR-T, offering rapid treatment and the prospect of quick patient recovery.
Immix Biopharma leverages its proprietary TME Normalization Technology to develop Tissue-Specific Therapeutics (TSTx) that precisely target cancerous tissues while minimizing systemic side effects. Their leading projects include the NEXICART-1 and NEXICART-2 clinical trials, which are currently testing the efficacy and safety of NXC-201 in patients with relapsed/refractory conditions.
In recent developments, Immix Biopharma has received multiple Orphan Drug Designations (ODD) from both the FDA and the European Medicines Agency (EMA) for NXC-201 in treating AL Amyloidosis and multiple myeloma. This designation provides significant regulatory and financial incentives, highlighting the therapy's potential impact on these challenging diseases.
Immix Biopharma's IMX-110 is another key product in its pipeline, aimed at treating soft tissue sarcoma. Currently under evaluation in Phase 1b/2a trials, IMX-110 has already been granted Orphan Drug and Rare Pediatric Disease Designations by the FDA, underscoring its potential for treating rare cancers.
The company has made significant strides over the past year, including receiving FDA investigational new drug clearance for NXC-201, advancing ongoing clinical trials, and forming strategic partnerships with leading research institutions such as Memorial Sloan Kettering Cancer Center. Their commitment to pioneering cell therapies is further evidenced by their recent awareness campaign, Be Proactive in AL™, aimed at improving the diagnosis and treatment of AL Amyloidosis.
With a robust clinical dataset and strong regulatory support, Immix Biopharma is well-positioned to bring transformative therapies to market, addressing unmet medical needs in autoimmune diseases and cancer. For more information, please visit www.immixbio.com.
Nexcella, a subsidiary of Immix Biopharma (NASDAQ: IMMX), reported promising clinical data from its Phase 1b/2 NEXICART-1 trial (NCT04720313) for NXC-201, a CAR-T therapy targeting relapsed/refractory multiple myeloma and AL amyloidosis. The data indicated a 92% overall response rate in multiple myeloma and a 100% response rate in AL amyloidosis patients, with median progression-free survival of 12.3 months. These results were presented at the EBMT 49th Annual Meeting in Paris. Nexcella aims to submit a BLA for FDA approval in both conditions after treating 100 patients for multiple myeloma and 30-40 for AL amyloidosis. The markets for multiple myeloma and AL amyloidosis are projected to expand significantly by 2027 and 2025, respectively, presenting substantial commercial opportunities for NXC-201.
Nexcella Inc., a subsidiary of Immix Biopharma (NASDAQ: IMMX), announced the presentation of updated clinical data for NXC-201, a CAR-T therapy for multiple myeloma and AL amyloidosis, at the 49th annual meeting of the European Society for Blood and Marrow Transplantation in Paris from April 23-26, 2023.
The updated data show a 90% overall response rate and a 59% complete response rate in relapsed/refractory multiple myeloma. Notably, NXC-201 achieved a 100% hematologic and organ response rate in AL amyloidosis patients. These results reflect the potential of NXC-201 as the first outpatient CAR-T therapy for these conditions.
Nexcella, a subsidiary of Immix Biopharma, Inc. (NASDAQ: IMMX), announced the publication of an editorial in Haematologica discussing the safety and efficacy of their BCMA CAR-T cell therapy, NXC-201. The therapy shows a 75% overall response rate, comparable to existing FDA-approved therapies. As of March 2023, 58 patients have been treated, primarily for multiple myeloma. The multiple myeloma market, valued at $13.9 billion in 2017, is projected to reach $28.7 billion by 2027. NXC-201 is under investigation for relapsed or refractory multiple myeloma and AL amyloidosis, demonstrating a favorable safety profile with outpatient treatment potential.
Nexcella, a subsidiary of Immix Biopharma (IMMX), announced promising results for NXC-201, a CAR-T therapy targeting relapsed/refractory multiple myeloma and AL amyloidosis. The treatment has shown a 100% complete hematologic response and a 100% organ response rate in 8 AL amyloidosis patients. A total of 58 patients have been treated, with notable safety data confirming outpatient treatment potential. The $13.9 billion multiple myeloma market is projected to grow to $28.7 billion by 2027, while the amyloidosis market is expected to reach $6 billion by 2025, according to industry research.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced on March 10, 2023, that it has no exposure to Silicon Valley Bank or Silvergate Bank. This statement underscores the company’s financial stability amidst recent banking sector concerns. ImmixBio is a clinical-stage biopharmaceutical company focusing on Tissue-Specific Therapeutics (TSTx)™ aimed at treating oncology and immuno-dysregulated diseases. With its proprietary SMARxT Tissue-Specific™ Platform, ImmixBio is innovating in the treatment landscape by targeting tumor microenvironments to enhance therapeutic efficacy.
FAQ
What is the current stock price of Immix Biopharma (IMMX)?
What is the market cap of Immix Biopharma (IMMX)?
What is Immix Biopharma, Inc.?
What are the main products of Immix Biopharma?
What is NXC-201?
What is the significance of the Orphan Drug Designation?
What recent achievements has Immix Biopharma made?
What is the Be Proactive in AL™ campaign?
What is IMX-110?
Where can I find more information about Immix Biopharma?
What are the key features of NXC-201?
Who are the key partners of Immix Biopharma?
